6-{2-[(E)-2-(2-[cyclopropylmethoxy]-3-methoxyphenyl)vinyl]-3H-imidazo[4,5-b]pyridin-3-yl}nicotinonitrile | 1233448-30-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 6-{2-[(E)-2-(2-[cyclopropylmethoxy]-3-methoxyphenyl)vinyl]-3H-imidazo[4,5-b]pyridin-3-yl}nicotinonitrile
• 英文别名: 6-[2-[(E)-2-[2-(cyclopropylmethoxy)-3-methoxyphenyl]ethenyl]imidazo[4,5-b]pyridin-3-yl]pyridine-3-carbonitrile
• CAS: 1233448-30-0
• 化学式: C₂₅H₂₁N₅O₂
• 分子量: 423.474
• InChiKey: JMOGTOPILKAXDX-ZRDIBKRKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  85.8
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• FUSED IMIDAZOLE DERIVATIVES AS TRPV3 ANTAGONIST
  申请人：Lingam V. S. Prasadarao

  公开号：US20110257193A1

  公开（公告）日：2011-10-20

  The present invention provides transient receptor potential vanilloid (TRPV) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.

  本发明提供了公式(I)的瞬时受体电位香草酰胺(TRPV)调节剂。具体来说，本文所描述的化合物对于治疗或预防由TRPV3调节的疾病、病症和/或障碍是有用的。本文还提供了用于制备所述化合物的过程，用于其合成的中间体，其制药组合物以及治疗或预防由TRPV3调节的疾病、病症和/或障碍的方法。
• US8344010B2
  申请人：——

  公开号：US8344010B2

  公开（公告）日：2013-01-01
• [EN] FUSED IMIDAZOLE DERIVATIVES AS TRPV3 ANTAGONIST<br/>[FR] DÉRIVÉS D'IMIDAZOLE CONDENSÉS COMME ANTAGONISTES DE TRPV3
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2010073128A2

  公开（公告）日：2010-07-01

  The present invention provides transient receptor potential vanilloid (TRPV) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRP V3. (Formula I) (I)